Compare Abbott Laboratories (ABT) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Rockwell Automation — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Rockwell Automation trades at $460.96 (market cap $52.18B). The key difference: Abbott Laboratories is far larger — about 3.2× Rockwell Automation's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | ROK | |
|---|---|---|
Market Cap | $166.94B | $52.18B |
Sector | Health | Industrials |
52-Week High | $136.62 | $495.08 |
52-Week Low | $82.57 | $328.67 |
Enterprise Value | $193.69B | $55.81B |
Dividend Yield | 2.63% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Rockwell Automation (ROK) trades at $468.9, down 0.59% today but near its 52-week high. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Revenue remains stable at $8.34B (2025), though net margins have softened to 10.41%. Recent news highlights AI infrastructure opportunities and product launches like FactoryTalk Orchestration, positioning ROK for industrial digital transformation growth.
Outlook remains positive with analyst consensus leaning toward Hold/Buy, targeting $463.86. Key opportunities include AI-driven industrial automation demand, while risks involve margin pressure and cyclical industry exposure. Valuation multiples (P/E 50.14) suggest premium pricing, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
